Log in
NASDAQ:FLXN

Flexion Therapeutics Stock Forecast, Price & News

$12.18
+0.03 (+0.25 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$11.80
Now: $12.18
$12.20
50-Day Range
$10.13
MA: $11.69
$13.43
52-Week Range
$5.01
Now: $12.18
$22.98
Volume241,039 shs
Average Volume745,623 shs
Market Capitalization$600.51 million
P/E RatioN/A
Dividend YieldN/A
Beta1.92
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
Read More
Flexion Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.83 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FLXN
CUSIPN/A
Phone781-305-7777
Employees288

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$72.96 million
Book Value($0.53) per share

Profitability

Net Income$-149,770,000.00
Net Margins-174.25%

Miscellaneous

Market Cap$600.51 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$12.18
+0.03 (+0.25 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FLXN News and Ratings via Email

Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

How has Flexion Therapeutics' stock been impacted by Coronavirus?

Flexion Therapeutics' stock was trading at $12.31 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FLXN stock has decreased by 1.1% and is now trading at $12.18.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Flexion Therapeutics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 1 hold rating, 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Flexion Therapeutics
.

When is Flexion Therapeutics' next earnings date?

Flexion Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Flexion Therapeutics
.

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics Inc (NASDAQ:FLXN) posted its quarterly earnings data on Wednesday, August, 5th. The specialty pharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.70) by $0.06. The specialty pharmaceutical company had revenue of $15.45 million for the quarter, compared to analyst estimates of $15.46 million.
View Flexion Therapeutics' earnings history
.

What price target have analysts set for FLXN?

13 brokers have issued 1-year price targets for Flexion Therapeutics' shares. Their forecasts range from $15.00 to $35.00. On average, they expect Flexion Therapeutics' stock price to reach $22.15 in the next twelve months. This suggests a possible upside of 81.9% from the stock's current price.
View analysts' price targets for Flexion Therapeutics
.

Who are some of Flexion Therapeutics' key competitors?

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Aduro BioTech (ADRO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Verastem (VSTM).

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the following people:
  • Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 68, Pay $1.06M)
  • Dr. Neil Bodick, Consultant (Age 73, Pay $657.6k)
  • Dr. Scott D. Kelley, Chief Medical Officer (Age 61, Pay $626.53k)
  • Mr. David A. Arkowitz, Chief Financial Officer (Age 59)
  • Scott Young, VP of Corp. Communications & Investor Relations

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Who are Flexion Therapeutics' major shareholders?

Flexion Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (1.06%), Assenagon Asset Management S.A. (0.05%) and Pacer Advisors Inc. (0.01%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, David Arkowitz, Mark S Levine, Mark Stejbach, Michael D Clayman and Samuel D Colella.
View institutional ownership trends for Flexion Therapeutics
.

Which institutional investors are selling Flexion Therapeutics stock?

FLXN stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC.
View insider buying and selling activity for Flexion Therapeutics
.

Which institutional investors are buying Flexion Therapeutics stock?

FLXN stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., and Pacer Advisors Inc.. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, David Arkowitz, Mark Stejbach, Michael D Clayman, and Samuel D Colella.
View insider buying and selling activity for Flexion Therapeutics
.

How do I buy shares of Flexion Therapeutics?

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Flexion Therapeutics' stock price today?

One share of FLXN stock can currently be purchased for approximately $12.18.

How big of a company is Flexion Therapeutics?

Flexion Therapeutics has a market capitalization of $600.51 million and generates $72.96 million in revenue each year. The specialty pharmaceutical company earns $-149,770,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Flexion Therapeutics employs 288 workers across the globe.

What is Flexion Therapeutics' official website?

The official website for Flexion Therapeutics is www.flexiontherapeutics.com.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.